Paradigm Asset Management Co. LLC Invests $1.50 Million in Smith & Nephew SNATS, Inc. $SNN

Paradigm Asset Management Co. LLC purchased a new position in shares of Smith & Nephew SNATS, Inc. (NYSE:SNN) in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 83,400 shares of the medical equipment provider’s stock, valued at approximately $1,502,000.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in SNN. GAMMA Investing LLC increased its stake in Smith & Nephew SNATS by 11.7% in the 3rd quarter. GAMMA Investing LLC now owns 3,837 shares of the medical equipment provider’s stock valued at $139,000 after buying an additional 401 shares during the period. Versant Capital Management Inc grew its holdings in shares of Smith & Nephew SNATS by 5.0% during the 3rd quarter. Versant Capital Management Inc now owns 8,912 shares of the medical equipment provider’s stock valued at $323,000 after acquiring an additional 423 shares in the last quarter. Inspire Investing LLC increased its stake in shares of Smith & Nephew SNATS by 7.1% in the third quarter. Inspire Investing LLC now owns 7,789 shares of the medical equipment provider’s stock worth $283,000 after acquiring an additional 516 shares during the last quarter. Cary Street Partners Financial LLC increased its stake in shares of Smith & Nephew SNATS by 3.8% in the second quarter. Cary Street Partners Financial LLC now owns 20,005 shares of the medical equipment provider’s stock worth $613,000 after acquiring an additional 725 shares during the last quarter. Finally, MAI Capital Management raised its holdings in shares of Smith & Nephew SNATS by 24.0% during the second quarter. MAI Capital Management now owns 4,371 shares of the medical equipment provider’s stock worth $134,000 after acquiring an additional 846 shares in the last quarter. 25.64% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

SNN has been the topic of a number of recent research reports. Canaccord Genuity Group boosted their target price on Smith & Nephew SNATS from $34.00 to $35.00 and gave the company a “hold” rating in a research note on Thursday. Kepler Capital Markets upgraded Smith & Nephew SNATS to a “strong-buy” rating in a report on Monday, November 17th. Wall Street Zen cut Smith & Nephew SNATS from a “strong-buy” rating to a “buy” rating in a research note on Saturday, February 21st. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Smith & Nephew SNATS in a research report on Wednesday, January 21st. Finally, Royal Bank Of Canada cut shares of Smith & Nephew SNATS from an “outperform” rating to a “sector perform” rating in a research note on Monday, December 15th. One investment analyst has rated the stock with a Strong Buy rating and five have given a Hold rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $36.25.

Smith & Nephew SNATS Stock Performance

Shares of SNN stock opened at $34.86 on Friday. Smith & Nephew SNATS, Inc. has a 12 month low of $23.91 and a 12 month high of $38.79. The company has a current ratio of 2.57, a quick ratio of 1.40 and a debt-to-equity ratio of 0.60. The business’s 50 day moving average is $34.40 and its two-hundred day moving average is $34.95.

Smith & Nephew SNATS Company Profile

Smith & Nephew plc is a global medical technology company specializing in the design, development and manufacture of advanced surgical devices, orthopaedic reconstruction implants, trauma and extremities products, sports medicine solutions and wound care therapies. Founded in 1856 in Hull, United Kingdom, the company has grown through both organic innovation and strategic acquisitions to offer a broad portfolio that addresses patient needs across joint replacement, minimally invasive surgery and wound healing.

In its orthopaedics business, Smith & Nephew provides hip and knee replacement systems, modular joint revision implants and biologic solutions for bone repair.